DGAP-News: MOLOGEN AG: Inclusion criteria for patients of the clinical trial with colorectal cancer medicine MGN1703 are expanded
(firmenpresse) - DGAP-News: MOLOGEN AG / Key word(s): Study
MOLOGEN AG: Inclusion criteria for patients of the clinical trial with
colorectal cancer medicine MGN1703 are expanded
05.05.2011 / 08:30
---------------------------------------------------------------------
Press release N 07/11 from 5 May 2011
MOLOGEN AG: Inclusion criteria for patients of the clinical trial with
colorectal cancer medicine MGN1703 are expanded
- Inclusion in clinical trial also possible without prior treatment with
Avastin(R) (Bevacizumab)
Berlin, 5 May 2011 - MOLOGEN AG has expanded the inclusion criteria for its
pivotal phase II/III clinical trial with the colorectal cancer medicine
MGN1703. With immediate effect, patients who exclusively received a
standard chemotherapy within their previous first-line treatment can now
also be included in the study.
The combination of standard chemotherapy with the medicine Avastin(R)
(active ingredient Bevacizumab) is hence no longer the sole prerequisite.
This expansion is possible because in the opinion of the company, the
efficacy of the immunomodulator MGN1703 is not influenced by Bevacizumab.
At the same time, this expansion of the inclusion criteria that has been
designed in co-operation with the participating study centers offers the
opportunity of gaining future market approval for the compound
independently of a quite specific first-line treatment.
MGN1703 - Immunotherapy against colorectal cancer
MGN1703 is a DNA-based compound that is being developed for the immune
therapy of metastasized, solid tumors. In clinical phase Ib, a very good
safety profile was already apparent. As expected, the medicine was very
well tolerated by the patients. In addition, the efficacy potential was
also very promising.
Clinical phase II/III study
MGN1703 is being tested since June 2010 in an official pivotal clinical
phase II/III study. The goal of the study is to show that a progression of
the cancer can be prevented for significantly longer than is possible with
the current available treatment methods.
The study is currently being conducted at several study centers in Germany,
Austria, France and Russia. First results will presumably be available
after an interim evaluation in the second half of 2011. This study marks a
further fundamental milestone within the clinical development program of
the company.
Information for patients
Further information about the clinical study is available on the homepage
of MOLOGEN AG:
www.mologen.com/data/English/03_08_Patientinfo.
Study registers
The study is registered on www.clinicaltrials.gov and www.cancer.gov.
Hotline
A study hotline at MOLOGEN AG for MGN1703 provides information individually
and in strict confidence in accordance with medical discretion to
interested doctors and patients on:
+49 (0)800 646 1703
About MOLOGEN AG
MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin
specializes in the research and development of innovative medicines on the
basis of DNA structures. The activities focus on numerous product
developments which are relevant to the immune system; on the one hand
vaccines against infectious diseases and on the other hand cancer
therapies. MOLOGEN AG is globally one of the few biotechnology companies
with well tolerated DNA-based cancer treatment in the clinical development
phase.
The stocks of MOLOGEN AG are listed in the PrimeStandard of the German
stock exchange
(ISIN DE0006637200).
Memberships in associations:
BIO Deutschland e.V. | DECHEMA - Society for chemical technology and
biotechnology e.V. | German industrial association of biotechnology (DIB)
| Association for the Promotion of Science and Humanities in Germany |
Association of German biotechnology companies (VBU) | Association of
researching manufacturers of pharmaceuticals e.V. (VFA) | Association of
the chemical industry e.V. (VCI)
MIDGE(R), dSLIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG.
MOLOGEN AG
PRESS SERVICE
Prof. Peter W. Huebner
Head of Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Tel: +49 - 30 - 84 17 88 - 50
huebner(at)mologen.com
INVESTOR RELATIONS:
Joerg PetraßTel: +49 - 30 - 84 17 88 - 13
Tel: +49 - 30 - 84 17 88 - 50
investor(at)mologen.com
External Investor Relations
Kirchhoff Consult AG
Janina Wismar
T: +49 - 40 - 60 91 86 - 50
F: +49 - 40 - 60 91 86 -16
janina.wismar(at)kirchhoff.de
Note about risk for future predictions
Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial figures,
developments of the financial situation or other financial figures or
statistical data, is to be understood as such forward-looking statements.
The company points out to investors that they should not rely on these
forward-looking statements as predictions about actual future events. The
company is not obligated and refuses to accept any liability for the
forward-looking statements and has no obligation to update such statements
in order to accurately reflect the current situation.
End of Corporate News
---------------------------------------------------------------------
05.05.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Deutschland
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: info(at)mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
123083 05.05.2011
Datum: 05.05.2011 - 08:30 Uhr
Sprache: Deutsch
News-ID 33970
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 298 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: MOLOGEN AG: Inclusion criteria for patients of the clinical trial with colorectal cancer medicine MGN1703 are expanded"
steht unter der journalistisch-redaktionellen Verantwortung von
MOLOGEN AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
